This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.

Start Date01 May 2026

Sponsor / Collaborator

VA Office of Research and Development

ChiCTR2600116372

/ Not yet recruitingPhase 4IIT

Efficacy and Safety of Microneedling Combined with Topical Medications for Psoriatic Nails

Start Date01 Dec 2025

Sponsor / Collaborator

China-Japan Friendship Hospital

ChiCTR2500112788

/ Not yet recruitingPhase 2IIT

Phase II Clinical Study of Imiquimod Cream Combined with Aipalolitovorelizumab Plus Albumin-Bound Paclitaxel/Carboplatin in the Neoadjuvant Treatment of Early-Stage High-Risk Triple-Negative Breast Cancer

Start Date30 Nov 2025

Sponsor / Collaborator

The First Affiliated Hospital of Nanchang University

100 Clinical Results associated with Imiquimod

100 Translational Medicine associated with Imiquimod

100 Patents (Medical) associated with Imiquimod

4,271

Literatures (Medical) associated with Imiquimod

31 Dec 2026·DRUG DELIVERY

Long-term management of psoriasis recurrence via modulation of cutaneous microbiome: synergistic topical therapy with blue light and aptamer-functionalized curcumin formulation

Article

Author: Li, Bingbing ; Chen, Jianmin ; Zheng, Tingting ; Lin, Xin ; Weng, Yumin ; Jin, Nan ; Liu, Tianhui ; Su, Yanhong ; Chen, Yaling ; Luo, Huangyu

The recurrence following the discontinuation of medication is a formidable challenge in managing psoriasis. Changes in the microbiome accompany the onset of psoriasis relapse, highlighting a potential therapeutic modality. To evaluate the superiority of the topical administration of aptamer-functionalized curcumin mesoporous silica (Apt-GA+Cur@μmS) plus blue light (BL) in restoring dysbiosis and intervening in recurrence in a murine model, a psoriasis relapse murine model with double imiquimod induction was established. With a BL-responsive shell, Apt-GA+Cur@μmS released curcumin (Cur) to assist BL to improve the preventative and therapeutic effects in the psoriasis relapse murine model, as evidenced by the psoriasis area and severity index, histology, splenic index, and dorsal IL-17A level. We also observed a negative correlation between splenic nitric oxide (NO) levels and the splenic index, indicating a possible mechanism by which Apt-GA+Cur@μmS&BL may function in the treatment of splenomegaly. Treatment with Apt-GA+Cur@μmS&BL exhibited a higher alpha diversity than the model group, with levels similar to those of healthy mice, indicating that this combination could adjust the composition of the dorsal microbiome to a healthier state. A reduction in the combined relative abundance of Staphylococcus, Streptococcus, and Corynebacterium as well as restoration of dysbiosis was also verified through 16S rDNA gene sequencing in vivo. Collectively, BL and Apt-GA+Cur@μmS cotherapy alleviates psoriasiform lesions in a double imiquimod-induced murine model by inhibiting IL-17A and increasing splenic NO. Additionally, this cotherapy restores the eubiosis of the dorsal lesions. Thus, it is a promising and innovative therapeutic modality for psoriasis inflammation alleviation and recurrence intervention.

31 Dec 2026·Human Vaccines & Immunotherapeutics

TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response

Article

Author: Su, Yu-Wen ; Su, Yu-Siang ; Tien, Chih-Feng ; Yu, Guann-Yi ; Tseng, Jen-Chih ; Chuang, Tsung-Hsien ; Chen, Linyi ; Imana, Zaida Nur ; Yang, Jing-Xing ; Liu, Yi-Ling ; Lin, Po-Yen ; Tsai, Wan-Ting ; Huang, Ming-Hsi ; Chen, Jen-Kun

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV), primarily affecting middle-aged and older individuals and often accompanied by severe pain and other complications. Vaccination is an effective preventive measure against this disease. In the present study, we evaluated the adjuvant activity of Toll-like receptor (TLR)9 and TLR7 agonists in combination with stimulator of interferon genes (STING) agonists for a VZV-glycoprotein E (gE)-based vaccine. Among the tested combinations, the CpG-2722 (TLR9 agonist) and 2'3'-c-di-AM(PS)2 (STING agonist) pairing exhibited potent immunostimulatory activity in immune cells and superior adjuvant activity for VZV-gE vaccines in a mouse models. Shingrix, a licensed herpes zoster vaccine, is administered intramuscularly. The CpG-2722/2'3'-c-di-AM(PS)2 combination adjuvanted VZV vaccine, administered intramuscularly, effectively induced higher gE-specific IgG responses than that induced by the Shingrix and imiquimod/2'3'-c-di-AM(PS)2 adjuvant vaccine. Notably, intranasal administration of the CpG-2722/2'3'-c-di-AM(PS)2 adjuvanted VZV vaccine to mice elicited a robust antigen-specific IgA response, which was barely detectable in intramuscularly administered vaccines. Two doses of the intranasal immunization, administered at a two-week interval, provided long-lasting protection, as antigen-specific IgG levels remained elevated for months without booster immunization. Further investigation into the functional mechanism revealed that CpG-2722 combined with 2'3'-c-di-AM(PS)2 induced a strong antigen-dependent T helper 1 (Th1) cytokine response, consistent with the antigen-independent cytokine-inducing properties of this adjuvant combination. This study demonstrates that the TLR9 and STING agonists formulated adjuvant induces a potent and long-lasting immune response, highlighting its potential as a promising adjuvant candidate for nasal VZV vaccines.

01 Jun 2026·COLLOIDS AND SURFACES B-BIOINTERFACES

Cerium-cobalt composite nanoparticles (CC NPs) as a multifunctional reactive oxygen species (ROS) scavenger for psoriasis therapy

Article

Author: Ren, Jie ; Zhang, Jiao ; Chen, Wenyu ; Yan, Jialin ; Yuan, Hui ; Sun, Hao ; Li, Yuhang ; Hu, Ting

Psoriasis is a chronic inflammatory disorder with a worldwide prevalence of 1-3 %, which has no cure. By inducing inflammation, keratinocyte hyperproliferation, and oxidative stress, reactive oxygen species (ROS) play a pivotal role in the pathogenesis of psoriasis. Although the clinical application of ROS-scavenging nanozymes is expected, their translation has been limited by complicated synthesis and high cost. To bypass these problems, in the present study, cerium cobalt composite nanoparticles (CC NPs) were fabricated via facile coprecipitation. The optimization results revealed that 8CC NPs (CeCo = 8:2) were optimal with uniform spherical morphology and enhanced oxygen vacancies, which enhanced the ROS-scavenging activities, and enabled the efficient scavenging of H₂O₂, O₂•^-, and •OH radicals. Then, 8CC NPs suppressed the intracellular ROS accumulation, inhibited proliferation, and attenuated the NF-κB inflammatory signaling in the IL-17-stimulated HaCaT keratinocytes. Additionally, in a murine imiquimod-induced psoriasis model, the treatment with 8CC NPs markedly alleviated the clinical symptoms, and no toxicity was observed. Therefore, CC NPs could serve as a novel, cost-effective, and biocompatible nanozyme platform with powerful ROS scavenging, simple synthesis, and promising inflammatory suppression, which provided strong support for their application in the translation of psoriasis. Given the inherent differences between murine models and human psoriasis, further studies are essential to validate the therapeutic potential of this nanozyme platform in clinical settings.

News (Medical) associated with Imiquimod

26 Feb 2026

·www.biospace.com

Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1

In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete lesion healing compared with 20% receiving investigator’s choice therapy (ICT) with an adjusted treatment difference of 37% (p = 0.027) in people living with HIV with refractory HSV infections The results were presented as a late-breaking oral presentation at the Conference on Retroviruses and Opportunistic Infections (CROI), which focuses on key clinical and scientific innovations in human retrovirus-associated diseases like HIV Wuppertal, Germany, February 25, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced superior efficacy results from a subgroup analysis of its pivotal Phase 3 trial (PRIOH-1) evaluating pritelivir vs. investigator’s choice in people living with HIV with refractory herpes simplex virus (HSV) infection. The results were presented as a late-breaking oral presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) on February 25, 2026, in Denver, USA. People living with HIV face a higher risk of severe, refractory HSV infections due to weakened immunity. HSV-2 also increases HIV acquisition risk, and co-infection can cause aggressive, prolonged, painful lesions and may accelerate HIV progression. Repeated antiviral use for treatment of HSV recurrence increases the risk of resistance, underscoring the urgent need for more effective HSV therapies for this vulnerable population. “Patients living with HIV who develop refractory HSV infections with or without acyclovir resistance often present with prolonged, atypical, and clinically challenging disease courses,” said Professor Jean-Michel Molina, University of Paris Cité, Department of Infectious Diseases, Saint-Louis and Lariboisière Hospitals APHP, Paris France , a principal investigator in the PRIOH-1 study who made the presentation at CROI. “The subgroup analysis from this Phase 3 trial provides important evidence that pritelivir can achieve meaningful lesion healing in this population, using an oral treatment option. These data add an important piece to our understanding of how refractory HSV can be managed in people living with HIV.” In the subgroup, people living with HIV represented 37.6% (38/101) of all immunocompromised patients enrolled in the PRIOH-1 Phase 3 trial and had a mean CD4 cell count of 334.8 cells/mm³. Among these patients, 81.6% (31/38) had refractory HSV (no clinical improvement in HSV lesions after ≥ 7 days of treatment), and 18.4% (7/38) had laboratory-confirmed acyclovir resistance. 40% of the study cohort had another underlying immunosuppressive condition. Similar to other subgroups, pritelivir achieved superior lesion healing of 61% (14/23) within up to 28 days of treatment, compared with 20% (3/15) for ICT, with an adjusted treatment difference of 37%, p = 0.027 [95%CI 7.6, 66.8] (post-hoc analysis). The majority (96%) of people living with HIV completed pritelivir treatment compared with 60% in the investigator’s choice treatment group. “People living with HIV often experience more complex clinical manifestations of HSV, which can make infections particularly difficult to treat,” said Cynthia Wat, CMO of Aicuris . “As an antiviral with a novel mechanism of action, pritelivir has shown efficacy in the treatment of refractory HSV infections with or without resistance (R±R) and may offer an important option for people living with HIV facing severe, refractory HSV disease.” Aicuris announced positive efficacy and favorable safety results for pritelivir at the 2026 Tandem Meetings earlier this month. The global, controlled, open-label comparative trial (PRIOH-1, NCT03073967 / Eudra-CT 2023-510088-37-00 ) included 101 randomized patients and 56 non-randomized patients with R±R HSV infection, including patients living with HIV, hematopoietic stem-cell and solid organ transplant patients, and patients with malignancies, autoimmune or inflammatory disorders. Patients were treated with either oral pritelivir or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod). Pritelivir demonstrated a favorable safety and tolerability profile. It was associated with fewer renal, electrolyte events and drug-related TEAE discontinuations (2.0%) compared with ICT (20.0%). The most common TEAEs that occurred while receiving pritelivir were headache (13.7%), diarrhea (11.8%), nausea (7.8%), decreased appetite (7.8%), vomiting (5.9%) and dizziness (5.9%). About Herpes Simplex Virus Herpes Simplex Virus (HSV) includes two types, HSV-1 and HSV-2, both of which cause lifelong infections. HSV-1 most commonly causes labial herpes, typically presenting as cold sores, while HSV-2 is the primary cause of genital herpes. HSV infections are characterized by recurrent, painful lesions and sores and, in severe cases, can lead to complications such as encephalitis, meningitis, disseminated disease, keratitis and neonatal herpes. HSV infections represent a substantial global public health burden. According to the World Health Organization, an estimated 3.8 billion people under the age of 50, or 64% of the global population, were infected with HSV-1 in 2020. 520 million people aged 15 to 49 were living with HSV-2. The disease burden is particularly high in immunocompromised patients, who are at increased risk of more severe, more frequent and treatment-refractory HSV infections. About Pritelivir Pritelivir, a novel helicase-primase inhibitor developed by Aicuris, targets both HSV-1 and HSV-2. These viruses are responsible for genital, oral, or disseminated infections with increasing severity and limited treatment options, particularly in immunocompromised patients where being treatment refractory or resistant to existing antivirals is a significant clinical challenge. Unlike traditional antivirals, pritelivir blocks viral DNA synthesis by inhibiting the helicase-primase complex, a mechanism distinct from marketed nucleoside analogues. Because of this distinct mode of action, pritelivir is active against strains resistant to nucleoside analog and foscarnet based therapies. 1 Earlier clinical trials in immunocompetent and immunocompromised individuals showed a favorable safety pro early signals of clinical efficacy compared to standard of care treatments like valacyclovir and foscarnet. Based on these results, pritelivir was granted FDA Breakthrough Therapy designation. In October 2025, Aicuris announced that pritelivir met its primary endpoint in the pivotal Phase 3 trial. About Aicuris Aicuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS ® , marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate, pritelivir, aims to address refractory HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. Aicuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future. Contact: Aicuris Anti-infective Cures AG Email: info@aicuris.com Trophic Communications Dr. Stephanie May and Anja Heuer Phone: +49 171 1855 682 Email: aicuris@trophic.eu 1 Sallée, L. and Boutolleau, D. (2024), Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review. Rev Med Virol, 34: e2574. Attachment CROI PR

Phase 3Clinical ResultBreakthrough TherapyQualified Infectious Disease Product

05 Feb 2026

·www.biospace.com

Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an adjusted treatment difference of 28.4% (p = 0.0047) Pritelivir demonstrated a favorable safety and tolerability profile, with fewer treatment-emergent adverse events and drug-related discontinuations compared to investigator’s choice Aicuris is on track to submit a New Drug Application (NDA) to the U.S. FDA in Q1 of 2026 The 2026 Tandem Meetings cover the latest research and breakthroughs in the evolving field of hematopoietic cell transplantation (HCT), cellular therapy and gene therapy Wuppertal, Germany, February 5, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced positive results from its pivotal Phase 3 trial (PRIOH-1, NCT03073967 ), evaluating pritelivir in immunocompromised patients with refractory herpes simplex virus (HSV) infections, with or without resistance (R±R). Pritelivir, a novel small molecule antiviral targeting the helicase-primase complex of HSV, demonstrated superior efficacy and a favorable safety and tolerability pro to investigator’s choice therapy (ICT). The results will be presented by study investigator Genovefa Papanicolaou, MD, in an Oral Late Breaker presentation at the 2026 Tandem Meetings on February 7, 2026, in Salt Lake City, USA. As announced in October 2025, the trial met its primary efficacy endpoint and demonstrated favorable safety and tolerability results. Pritelivir achieved a clinically meaningful and statistically significant superiority in lesion healing of 62.7% compared to 34.0% for ICT, with an adjusted treatment difference of 28.4% (p = 0.0047). Pritelivir was associated with fewer drug-related treatment-emergent adverse events (TEAEs), including renal, electrolyte and drug-related TEAEs, leading to discontinuations compared with ICT (2.0% vs. 20% respectively). The most common TEAEs were headache, diarrhea, nausea, decreased appetite, vomiting and dizziness with a ≥5% incidence. “Current therapeutic options for hematopoietic cell transplant patients with refractory or resistant herpes simplex viral infection are limited by poor response rates, significant toxicities, and the burden of daily intravenous infusions in a healthcare setting,” said Genovefa Papanicolaou, MD, Clinical Director of Infectious Disease Service at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell College of Medicine . Pritelivir addresses a critical unmet medical need for an oral agent offering statistically superior and clinically meaningful lesion healing with fewer side effects. It has the potential to significantly improve both clinical outcomes and quality of life for these vulnerable patients.” “For more than two decades, there has been no innovation in antiviral medicines for HSV, leaving clinicians with limited treatment options for patients who do not respond to existing antivirals. By targeting an essential step in the virus’s replication process, pritelivir offers a novel approach that can overcome current antiviral resistance,” Cynthia Wat, MD, CMO of Aicuris , added. “Together, these results mark a pivotal moment for patients with refractory HSV infections, supporting pritelivir’s potential to redefine the standard of care for patients at high risk of morbidity and mortality. We look forward to bringing it swiftly to those with few effective and well tolerated alternatives.” The global, controlled, open-label comparative trial ( NCT03073967 / Eudra-CT 2023-510088-37-00 ) randomized and treated a total of 101 immunocompromised patients with R±R HSV infection, including transplant recipients (hematopoietic stem-cell and solid organ), patients with malignancies, autoimmune or inflammatory disorders, and patients with an HIV infection. An additional 56 patients were treated in the non-randomized part of the trial. Participants received either oral pritelivir (100 mg daily, 400 mg loading dose on the first day of therapy) or ICT (IV foscarnet, IV/topical cidofovir or topical imiquimod) for up to 28 days, with the option to extend treatment to 42 days, if lesion improvement was observed. About Herpes Simplex Virus Herpes Simplex Virus (HSV) includes two types, HSV-1 and HSV-2, both of which cause lifelong infections. HSV-1 most commonly causes labial herpes, typically presenting as cold sores, while HSV-2 is the primary cause of genital herpes. HSV infections are characterized by recurrent, painful lesions and sores and, in severe cases, can lead to complications such as encephalitis, meningitis, disseminated disease, keratitis and neonatal herpes. HSV infections represent a substantial global public health burden. According to the World Health Organization, an estimated 3.8 billion people under the age of 50, or 64% of the global population, were infected with HSV-1 in 2020. 520 million people aged 15 to 49 were living with HSV-2. The disease burden is particularly high in immunocompromised patients, who are at increased risk of more severe, more frequent and treatment-refractory HSV infections. About Pritelivir Pritelivir, a novel helicase-primase inhibitor developed by Aicuris, targets both HSV-1 and HSV-2. These viruses are responsible for genital, oral, or disseminated infections with increasing severity and limited treatment options, particularly in immunocompromised patients where being treatment refractory or resistant to existing antivirals is a significant clinical challenge. Unlike traditional antivirals, pritelivir blocks viral DNA synthesis by inhibiting the helicase-primase complex, a mechanism distinct from marketed nucleoside analogues. Because of this distinct mode of action, pritelivir is active against strains resistant to nucleoside analog-and foscarnet based therapies. 1 Earlier clinical trials in immunocompetent and immunocompromised individuals showed a favorable safety pro early signals of clinical efficacy compared to standard of care treatments like valacyclovir and foscarnet. Based on these results, pritelivir was granted FDA Breakthrough Therapy designation. In October 2025, Aicuris announced that pritelivir met its primary endpoint in the pivotal Phase 3 trial. The company expects to marketing authorization with the U.S. FDA in Q1 of 2026. About Aicuris Aicuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS ® , marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate, pritelivir, aims to address refractory HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. Aicuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future. Contact: Aicuris Anti-infective Cures AG info@aicuris.com Trophic Communications Dr. Stephanie May and Anja Heuer Phone: +49 171 1855 682 Email: aicuris@trophic.eu 1 Sallée, L. and Boutolleau, D. (2024), Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review. Rev Med Virol, 34: e2574. Attachment Tandem Data PR

Phase 3Clinical ResultBreakthrough Therapy

01 Dec 2025

·www.drugs.com

Compounded Imiquimod Ointment May Be Beneficial for Some Ocular Surface Cancers

MONDAY, Dec. 1, 2025 -- Compounded imiquimod 5 percent ointment may be safe and effective for diffuse conjunctival melanoma in situ (MIS) or ocular surface squamous neoplasia (OSSN), according to a case series study published online Nov. 26 in JAMA Ophthalmology . R. Christopher Bowen, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined the outcomes of compounded imiquimod 5 percent ointment for diffuse conjunctival MIS or OSSN in an interventional case series study. The case series included five patients with a histological diagnosis of conjunctival intraepithelial neoplasia (CIN), conjunctival squamous cell carcinoma, conjunctival MIS, or conjunctival melanoma with adjacent clinical primary acquired melanosis (PAM), who received compounded imiquimod ointment applied to the conjunctival surface five days a week for at least 12 weeks. The researchers observed complete clinical and histological response of CIN with moderate dysplasia, partial histological response, and no histological recurrence of positive margins of squamous cell carcinoma excision at 12 weeks of treatment. Partial clinical response of diffuse MIS with mild persistence of epithelial pigmentation at the corneal limbus at the 7-o'clock position was seen at 12 weeks of treatment; however, in the areas of initial map biopsy, there was complete histological response. Complete clinical and histological response of PAM was seen at 15 weeks of treatment. All five patients experienced ophthalmic adverse events, only affecting the ocular surface and eyelids; within one to two weeks of drug holiday or completing treatment, all ocular surface adverse events resolved. "Further studies with prospective follow-up, controls, and larger numbers are needed to assess longer-term risks and benefits of this therapy," the authors write. One author disclosed ties to Elsevier. Abstract/Full Text (subscription or payment may be required) Editorial (subscription or payment may be required)

Clinical Result

100 Deals associated with Imiquimod

External Link

KEGG	Wiki	ATC	Drug Bank
D02500	Imiquimod	D06BB10	DB00724

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Warts	United States	Graceway Pharmaceuticals LLC	24 Mar 2011
Warts	United States	Bausch Health US LLC	24 Mar 2011
Basal Cell Carcinoma	United States	Bausch Health US LLC	14 Jul 2004
Actinic Keratosis	European Union	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	Iceland	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	Liechtenstein	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	Norway	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	European Union	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	Iceland	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	Liechtenstein	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	Norway	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Condylomata Acuminata	United States	Bausch Health US LLC	27 Feb 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cervical Intraepithelial Neoplasia	Phase 3	Netherlands	Meda Pharma GmbH & Co. KG	01 Dec 2014
Uterine Cervical Dysplasia	Phase 3	Netherlands	Meda Pharma GmbH & Co. KG	01 Dec 2014
Hutchinson's Melanotic Freckle	Phase 3	France	Meda Pharma GmbH & Co. KG	01 Dec 2012
Lentigo maligna melanoma	Phase 3	France	Meda Pharma GmbH & Co. KG	01 Dec 2012
Carcinoma in Situ	Phase 2	United States	Telormedix SA	01 Feb 2013
Carcinoma in situ of bladder	Phase 2	United States	Telormedix SA	01 Feb 2013
Non-Muscle Invasive Bladder Neoplasms	Phase 2	United States	Telormedix SA	01 Feb 2013
Port-Wine Stain	Phase 2	United States	Graceway Pharmaceuticals, LLC	01 Oct 2008
Capillary Hemangioma	Phase 2	Canada	Graceway Pharmaceuticals, LLC	01 Mar 2005
Mycosis Fungoides	Clinical	-	Bausch Health Americas, Inc.	01 Apr 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01059110 (VRAIE, Pubmed \| Ann Dermatol Venereol)	Phase 3	Plantar wart	174	5% 5-fluorouracil cream	rauhtmlwto(skvzvhhfsi) = dxmpyodwah eleshnoktx (fzhdzjbrch )	Negative	01 Sep 2025
NCT01059110 (VRAIE, Pubmed \| Ann Dermatol Venereol)	Phase 3	Plantar wart	174	5% imiquimod cream	rauhtmlwto(skvzvhhfsi) = iwllxpvpwq eleshnoktx (fzhdzjbrch )	Negative	01 Sep 2025
NCT04883645 (CTgov)	Early Phase 1	Squamous cell carcinoma of the oral cavity	16	Imiquimod (Experimental: Imiquimod)	whswjgynxt = hnvkxmtcpd qashgusskv (vixripcvda, qyoluglecm - hgbxkrqmfs) View more	-	28 Jan 2025
NCT04883645 (CTgov)	Early Phase 1	Squamous cell carcinoma of the oral cavity	16	Imiquimod (Correlative: Change in Antitumor Immune Cell Count After Imiquimod Immunotherapy.)	vadzbmkjpn(qgkdwkbofu) = cfsldxzgug zilubxaarc (otgocicxgp, drdmbwtqbd - zjnplslbzo) View more	-	28 Jan 2025
NCT04883645 (Pubmed \| Front Immunol)	Early Phase 1	Squamous cell carcinoma of the oral cavity Neoadjuvant	-	Imiquimod	hevnrkmvnz(xpsfwzehhr) = grades 1-3 sdxvrclqod (npeutzydtz ) View more	Positive	27 Jan 2025
NCT01861535 \| EUCTR2012-002052-17-AT (PITVIN, ESGO2024) Manual	Phase 3	Squamous Intraepithelial Lesions	38	Imiquimod	fhdzlnpquu(huaarqxota) = The immune microenvironment of complete responders to imiquimod show a coordinated influx of CD14+ inflammatory myeloid cells and type 1 CD4+ and CD3+CD8+ T cells, both in and between epithelial and stromal compartments. The persistent lesions did not display such a coordinated immune response. Importantly, recurrent vHSIL are able to respond to imiquimod in a comparable manner to primary vHSIL when a pre-existent coordinated immune infiltrate is present. snazfoeszr (hfqmzdorgp )	Positive	10 Mar 2024
AAD2024	Not Applicable	Hutchinson's Melanotic Freckle	1,326	5% Imiquimod Monotherapy	olcrrfcxfd(hpasbxqtrb) = zxsosxywlv xlcfrlyffs (mpjpuiuuim, 76 - 87) View more	Positive	08 Mar 2024
EADV2023	Phase 3	Hutchinson's Melanotic Freckle Neoadjuvant	283	Imiquimod	cvnbhxxeyc(iorsfoitiq) = urtrunckzs hebmozeqzw (uwwiclrujk ) View more	Positive	11 Oct 2023
EADV2023	Phase 3	Hutchinson's Melanotic Freckle Neoadjuvant	283	Placebo	cvnbhxxeyc(iorsfoitiq) = uvlxpbegys hebmozeqzw (uwwiclrujk ) View more	Positive	11 Oct 2023
SGO2023	Not Applicable	Vulvar intraepithelial neoplasia	264	Imiquimod	jjndkgznoo(axgddkkuul) = tlncvqvxzu ttlozibnkq (hdqypikgci ) View more	Positive	01 Sep 2023
WCD2023	Not Applicable	Basal Cell Carcinoma \| Actinic Keratosis	66	Topical Imiquimod	ooorjryeqc(xdpahgontg) = mveruvigfv qytismemkm (pihdllsawv ) View more	-	05 Jul 2023
EADV2023	Not Applicable	Basal Cell Carcinoma \| Actinic Keratosis	-	Topical Imiquimod	brasundiil(lpfnlduxmq) = erythema, scales, and crusts, itching, or pain. No systemic adverse events were noted, particularly affecting the function of the transplanted organ cljsuqwycd (taxhmntseq )	-	18 May 2023
NCT02135419 (ANCHOR, CTgov)	Phase 3	Human Papillomavirus Infection \| Condylomata Acuminata \| Squamous Intraepithelial Lesions ... View more	4,446	infrared photocoagulation therapy+imiquimod+fluorouracil (Arm I (Treatment))	whlndzahhe = dhvklaxqfm tkzixsgcvc (tpkvkzudrt, lquoyrduwa - iysyaqqida) View more	-	02 Dec 2022
NCT02135419 (ANCHOR, CTgov)	Phase 3		4,446	clinical observation (Arm II (Active Monitoring) (Closed Since SEP2021))	whlndzahhe = gzhlujtunj tkzixsgcvc (tpkvkzudrt, fhebyagvku - iutwtyibjc) View more	-	02 Dec 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis